Lapatinib, nilotinib and lomitapide inhibit haemozoin formation in malaria parasites. de Sousa, A. C. C., Maepa, K., Combrinck, J. M., & Egan, T. J. Molecules, 25(7):1571, Multidisciplinary Digital Publishing Institute, mar, 2020. ![Lapatinib, nilotinib and lomitapide inhibit haemozoin formation in malaria parasites [link]](https://bibbase.org/img/filetypes/link.svg "link")
Paper doi abstract bibtex With the continued loss of antimalarials to resistance, drug repositioning may have a role in maximising efficiency and accelerating the discovery of new antimalarial drugs. Bayesian statistics was previously used as a tool to virtually screen USFDA approved drugs for predicted $β$-haematin (synthetic haemozoin) inhibition and in vitro antimalarial activity. Here, we report the experimental evaluation of nine of the highest ranked drugs, confirming the accuracy of the model by showing an overall 93% hit rate. Lapatinib, nilotinib, and lomitapide showed the best activity for inhibition of $β$-haematin formation and parasite growth and were found to inhibit haemozoin formation in the parasite, providing mechanistic insights into their mode of antimalarial action. We then screened the USFDA approved drugs for binding to the $β$-haematin crystal, applying a docking method in order to evaluate its performance. The docking method correctly identified imatinib, lapatinib, nilotinib, and lomitapide. Experimental evaluation of 22 of the highest ranked purchasable drugs showed a 24% hit rate. Lapatinib and nilotinib were chosen as templates for shape and electrostatic similarity screening for lead hopping using the in-stock ChemDiv compound catalogue. The actives were novel structures worthy of future investigation. This study presents a comparison of different in silico methods to identify new haemozoin-inhibiting chemotherapeutic alternatives for malaria that proved to be useful in different ways when taking into consideration their strengths and limitations.
@article{DeSousa2020,
abstract = {With the continued loss of antimalarials to resistance, drug repositioning may have a role in maximising efficiency and accelerating the discovery of new antimalarial drugs. Bayesian statistics was previously used as a tool to virtually screen USFDA approved drugs for predicted $\beta$-haematin (synthetic haemozoin) inhibition and in vitro antimalarial activity. Here, we report the experimental evaluation of nine of the highest ranked drugs, confirming the accuracy of the model by showing an overall 93{\%} hit rate. Lapatinib, nilotinib, and lomitapide showed the best activity for inhibition of $\beta$-haematin formation and parasite growth and were found to inhibit haemozoin formation in the parasite, providing mechanistic insights into their mode of antimalarial action. We then screened the USFDA approved drugs for binding to the $\beta$-haematin crystal, applying a docking method in order to evaluate its performance. The docking method correctly identified imatinib, lapatinib, nilotinib, and lomitapide. Experimental evaluation of 22 of the highest ranked purchasable drugs showed a 24{\%} hit rate. Lapatinib and nilotinib were chosen as templates for shape and electrostatic similarity screening for lead hopping using the in-stock ChemDiv compound catalogue. The actives were novel structures worthy of future investigation. This study presents a comparison of different in silico methods to identify new haemozoin-inhibiting chemotherapeutic alternatives for malaria that proved to be useful in different ways when taking into consideration their strengths and limitations.},
author = {de Sousa, Ana Carolina C. and Maepa, Keletso and Combrinck, Jill M. and Egan, Timothy J.},
doi = {10.3390/molecules25071571},
file = {:C$\backslash$:/Users/01462563/AppData/Local/Mendeley Ltd./Mendeley Desktop/Downloaded/de Sousa et al. - 2020 - Lapatinib, nilotinib and lomitapide inhibit haemozoin formation in malaria parasites.pdf:pdf},
issn = {1420-3049},
journal = {Molecules},
keywords = {OA,Plasmodium,antimalarials,docking,drug repurposing,fund{\_}ack,haematin,haemozoin,original,tyrosine kinase inhibitors,virtual screening,$\beta$},
mendeley-tags = {OA,fund{\_}ack,original},
month = {mar},
number = {7},
pages = {1571},
pmid = {32235391},
publisher = {Multidisciplinary Digital Publishing Institute},
title = {{Lapatinib, nilotinib and lomitapide inhibit haemozoin formation in malaria parasites}},
url = {https://www.mdpi.com/1420-3049/25/7/1571},
volume = {25},
year = {2020}
}
Downloads: 0
{"_id":"pyX6wQqx7hrp7oqWc","bibbaseid":"desousa-maepa-combrinck-egan-lapatinibnilotinibandlomitapideinhibithaemozoinformationinmalariaparasites-2020","authorIDs":[],"author_short":["de Sousa, A. C. C.","Maepa, K.","Combrinck, J. M.","Egan, T. J."],"bibdata":{"bibtype":"article","type":"article","abstract":"With the continued loss of antimalarials to resistance, drug repositioning may have a role in maximising efficiency and accelerating the discovery of new antimalarial drugs. Bayesian statistics was previously used as a tool to virtually screen USFDA approved drugs for predicted $β$-haematin (synthetic haemozoin) inhibition and in vitro antimalarial activity. Here, we report the experimental evaluation of nine of the highest ranked drugs, confirming the accuracy of the model by showing an overall 93% hit rate. Lapatinib, nilotinib, and lomitapide showed the best activity for inhibition of $β$-haematin formation and parasite growth and were found to inhibit haemozoin formation in the parasite, providing mechanistic insights into their mode of antimalarial action. We then screened the USFDA approved drugs for binding to the $β$-haematin crystal, applying a docking method in order to evaluate its performance. The docking method correctly identified imatinib, lapatinib, nilotinib, and lomitapide. Experimental evaluation of 22 of the highest ranked purchasable drugs showed a 24% hit rate. Lapatinib and nilotinib were chosen as templates for shape and electrostatic similarity screening for lead hopping using the in-stock ChemDiv compound catalogue. The actives were novel structures worthy of future investigation. This study presents a comparison of different in silico methods to identify new haemozoin-inhibiting chemotherapeutic alternatives for malaria that proved to be useful in different ways when taking into consideration their strengths and limitations.","author":[{"propositions":["de"],"lastnames":["Sousa"],"firstnames":["Ana","Carolina","C."],"suffixes":[]},{"propositions":[],"lastnames":["Maepa"],"firstnames":["Keletso"],"suffixes":[]},{"propositions":[],"lastnames":["Combrinck"],"firstnames":["Jill","M."],"suffixes":[]},{"propositions":[],"lastnames":["Egan"],"firstnames":["Timothy","J."],"suffixes":[]}],"doi":"10.3390/molecules25071571","file":":C$\\$:/Users/01462563/AppData/Local/Mendeley Ltd./Mendeley Desktop/Downloaded/de Sousa et al. - 2020 - Lapatinib, nilotinib and lomitapide inhibit haemozoin formation in malaria parasites.pdf:pdf","issn":"1420-3049","journal":"Molecules","keywords":"OA,Plasmodium,antimalarials,docking,drug repurposing,fund_ack,haematin,haemozoin,original,tyrosine kinase inhibitors,virtual screening,$β$","mendeley-tags":"OA,fund_ack,original","month":"mar","number":"7","pages":"1571","pmid":"32235391","publisher":"Multidisciplinary Digital Publishing Institute","title":"Lapatinib, nilotinib and lomitapide inhibit haemozoin formation in malaria parasites","url":"https://www.mdpi.com/1420-3049/25/7/1571","volume":"25","year":"2020","bibtex":"@article{DeSousa2020,\r\nabstract = {With the continued loss of antimalarials to resistance, drug repositioning may have a role in maximising efficiency and accelerating the discovery of new antimalarial drugs. Bayesian statistics was previously used as a tool to virtually screen USFDA approved drugs for predicted $\\beta$-haematin (synthetic haemozoin) inhibition and in vitro antimalarial activity. Here, we report the experimental evaluation of nine of the highest ranked drugs, confirming the accuracy of the model by showing an overall 93{\\%} hit rate. Lapatinib, nilotinib, and lomitapide showed the best activity for inhibition of $\\beta$-haematin formation and parasite growth and were found to inhibit haemozoin formation in the parasite, providing mechanistic insights into their mode of antimalarial action. We then screened the USFDA approved drugs for binding to the $\\beta$-haematin crystal, applying a docking method in order to evaluate its performance. The docking method correctly identified imatinib, lapatinib, nilotinib, and lomitapide. Experimental evaluation of 22 of the highest ranked purchasable drugs showed a 24{\\%} hit rate. Lapatinib and nilotinib were chosen as templates for shape and electrostatic similarity screening for lead hopping using the in-stock ChemDiv compound catalogue. The actives were novel structures worthy of future investigation. This study presents a comparison of different in silico methods to identify new haemozoin-inhibiting chemotherapeutic alternatives for malaria that proved to be useful in different ways when taking into consideration their strengths and limitations.},\r\nauthor = {de Sousa, Ana Carolina C. and Maepa, Keletso and Combrinck, Jill M. and Egan, Timothy J.},\r\ndoi = {10.3390/molecules25071571},\r\nfile = {:C$\\backslash$:/Users/01462563/AppData/Local/Mendeley Ltd./Mendeley Desktop/Downloaded/de Sousa et al. - 2020 - Lapatinib, nilotinib and lomitapide inhibit haemozoin formation in malaria parasites.pdf:pdf},\r\nissn = {1420-3049},\r\njournal = {Molecules},\r\nkeywords = {OA,Plasmodium,antimalarials,docking,drug repurposing,fund{\\_}ack,haematin,haemozoin,original,tyrosine kinase inhibitors,virtual screening,$\\beta$},\r\nmendeley-tags = {OA,fund{\\_}ack,original},\r\nmonth = {mar},\r\nnumber = {7},\r\npages = {1571},\r\npmid = {32235391},\r\npublisher = {Multidisciplinary Digital Publishing Institute},\r\ntitle = {{Lapatinib, nilotinib and lomitapide inhibit haemozoin formation in malaria parasites}},\r\nurl = {https://www.mdpi.com/1420-3049/25/7/1571},\r\nvolume = {25},\r\nyear = {2020}\r\n}\r\n","author_short":["de Sousa, A. C. C.","Maepa, K.","Combrinck, J. M.","Egan, T. J."],"key":"DeSousa2020","id":"DeSousa2020","bibbaseid":"desousa-maepa-combrinck-egan-lapatinibnilotinibandlomitapideinhibithaemozoinformationinmalariaparasites-2020","role":"author","urls":{"Paper":"https://www.mdpi.com/1420-3049/25/7/1571"},"keyword":["OA","Plasmodium","antimalarials","docking","drug repurposing","fund_ack","haematin","haemozoin","original","tyrosine kinase inhibitors","virtual screening","$β$"],"metadata":{"authorlinks":{}},"downloads":0},"bibtype":"article","biburl":"https://drive.google.com/uc?export=download&id=1-JLqZ7RwZ3VC2d6ErLGHAtOeMRS_7GCz","creationDate":"2020-06-18T08:49:34.133Z","downloads":0,"keywords":["oa","plasmodium","antimalarials","docking","drug repurposing","fund_ack","haematin","haemozoin","original","tyrosine kinase inhibitors","virtual screening","$β$"],"search_terms":["lapatinib","nilotinib","lomitapide","inhibit","haemozoin","formation","malaria","parasites","de sousa","maepa","combrinck","egan"],"title":"Lapatinib, nilotinib and lomitapide inhibit haemozoin formation in malaria parasites","year":2020,"dataSources":["FdCBAxFeyKEmJd8WK","wrEvssexmuYudwQw9","9bX4N36CTXtCXNFMd","Krmt6gt9ktB2s6ARh"]}